An interactive molecular documentary

DMT and Cluster Headache

An exploration of why people with cluster headache report rapid relief from DMT, what recent literature can and cannot tell us, and how serotonin signalling, oxygen, sigma-1, calcium and redox energy may fit into the wider biology of an attack.

MOLECULAR INPUTCLUSTER ATTACK CIRCUITDMTtryptamineFast gate5-HT2A5-HT1B/1DSlow terrainsigma-1 · redoxMAM calciumattackswitchhypothalamustrigeminalautonomicvascular
What this documentary follows

Cluster headache patients have described DMT as an unusually rapid abortive, and an interim 2026 international survey has brought that signal into the medical literature. This piece does not assume one answer. It follows the biology a reader needs to understand the leading possibilities: fast serotonin-linked attack circuitry, established cluster abortives such as oxygen and triptans, sigma-1 stress biology, mitochondrial calcium, redox balance, methylation and the newer metabolite findings in cluster headache.

Established cell biologyDirect experimental findingMechanistic inferenceUnresolved mechanism
Begin
Bioenergetics

A neuron's energy problem

Plasma membraneCytosolNucleusEndoplasmic reticulumMitochondrionMAM contact siteGlucose
  • Glucose
  • ER
  • Mitochondrion
  • MAM contact

A neuron is an energy emergency in slow motion. It spends most of its ATP holding electrochemical gradients across its membranes - pumping sodium out, potassium in, calcium down - so that it can fire again. Interrupt that supply and the gradients decay within minutes.

Most of that ATP comes from oxidative phosphorylation inside mitochondria, which needs a steady stream of oxygen. A much smaller, faster supply comes from glycolysis in the cytosol, which can run without oxygen but yields far less per glucose.

This is one reason the cluster-headache question cannot be reduced to a single receptor. A rapid abortive signal points toward fast neural circuitry, but the nervous system carrying that signal is also shaped by oxygen handling, mitochondrial stress, calcium flow and redox balance.

Where we are going
We begin with how a neuron makes energy, then zoom into the ER-mitochondrial contact site, sigma-1 biology and DMT. From there we return to cluster headache through serotonin-linked attack circuitry, oxygen, redox balance and recent metabolite findings.
The protective effect we build toward is:
Bioenergetics

From glucose to pyruvate

Glycolysis - cytosolic backbone
  1. 1Glucose
  2. 2Glucose-6-phosphate
  3. 3Fructose-6-phosphate
  4. 4Fructose-1,6-bisphosphate
  5. 5Glyceraldehyde-3-phosphate
  6. 6Phosphoenolpyruvate
  7. 7Pyruvate
2net ATP
2NADH
2pyruvate
per glucose

In the cytosol, one glucose is invested with two ATP, split into two three-carbon sugars, and harvested back for a net 2 ATP, 2 NADH and 2 pyruvate. No oxygen is consumed directly in these ten reactions.

But there is a catch built into step six: oxidising the sugar reduces NAD⁺ to NADH. Glycolysis can only keep running if that NAD⁺ is regenerated. In oxygen, the mitochondrion does this. In hypoxia, the cell must find another way - a point that will matter enormously later.

Note
Glycolysis can produce ATP without directly using oxygen, but continued glycolysis requires regeneration of NAD⁺.

Each pyruvate is then carried into the mitochondrial matrix through the mitochondrial pyruvate carrier, where pyruvate dehydrogenase converts it to acetyl-CoA, releasing CO₂ and reducing another NAD⁺ to NADH. That acetyl-CoA is the fuel the Krebs cycle burns next.

Bioenergetics

The Krebs cycle

12345678CitrateIsocitrateα-KetoglutarateSuccinyl-CoASuccinateFumarateMalateOxaloacetateAcetyl-CoAenters here(from pyruvate)
Tap a numbered enzyme
Step 3 · Isocitrate dehydrogenase (IDH)Ca²⁺-regulated
Substrate
Isocitrate
Product
α-Ketoglutarate
Cofactor
NAD⁺
Produces
NADH, CO₂

Ca²⁺-activated. First oxidative decarboxylation and a principal calcium-sensitive control point.

Inside the matrix, each acetyl-CoA is fed into a cycle that strips it of electrons. Per acetyl-CoA the cycle yields 3 NADH, 1 FADH₂, 1 GTP/ATP and 2 CO₂. The NADH and FADH₂ are the real prize: energetic carriers that will drive the electron transport chain.

Three enzymes here are switched up by calcium. That matters because any mechanism involving sigma-1, MAM calcium or mitochondrial stress has to pass through this basic metabolic control point. When mitochondrial calcium rises into a controlled range, it accelerates exactly these reactions, matching fuel oxidation to demand.

The three calcium-sensitive control points
  • Pyruvate dehydrogenase - activated indirectly, via pyruvate dehydrogenase phosphatase.
  • Isocitrate dehydrogenase - directly activated.
  • α-Ketoglutarate dehydrogenase - directly activated.
Calcium activation of these dehydrogenases is
Bioenergetics

Electrons, oxygen and ATP

Intermembrane space (H⁺ accumulates)MatrixNADHFADH₂QcIIIIIIIVVATP synthaseO₂H₂OATP
  • electrons
  • protons (H⁺)
  • O₂
  • H₂O
  • ATP
Complex IV
Electrons to O₂ → H₂O

Cytochrome c oxidase. Donates electrons to molecular oxygen, which - with protons - forms water. This is where oxygen is consumed; without O₂ the whole chain backs up.

NADH and FADH₂ deliver their electrons to the chain. As electrons hop from Complex I (or II) to coenzyme Q, through Complex III, along cytochrome c to Complex IV, the complexes pump protons into the intermembrane space, building an electrochemical gradient.

At Complex IV, oxygen is the final electron acceptor: it combines with electrons and protons to form water. Then protons flood back through ATP synthase, whose rotation forges ATP from ADP and inorganic phosphate.

This is where the great majority of a neuron's ATP is made - and where the dependence on oxygen is absolute.

ATP produced (illustrative)
0
~30-32 ATP
per glucose*
* An approximate figure
The familiar “30-32 ATP per glucose” is an estimate, not a constant. The real yield varies with cell type, which shuttle moves cytosolic NADH into mitochondria, how much the membrane leaks protons, and the metabolic state of the cell.
The contact site

Where the ER meets the mitochondrion

ER lumen(calcium store)ER membraneCytosolic gap · MAMmembranes approach - they do not fusehigh-Ca²⁺ microdomainOuter membraneMatrix(TCA cycle)GRP75IP₃RVDAC1MCUSigma-1BiPCa²⁺Route: ER lumen → IP₃R → MAM microdomain → VDAC1 → intermembrane space → MCU → matrix

Zoom out from the matrix and something striking appears: the mitochondrion sits pressed against the endoplasmic reticulum. At these junctions - the mitochondria-associated ER membraneMAMMitochondria-associated ER membrane - the nanometre-scale contact site where the endoplasmic reticulum presses against the mitochondrion without fusing., or MAM - the two organelles come within nanometres of each other but do not fuse.

This narrow gap is not empty. A molecular machine spans it. The IP₃ receptor in the ER membrane is tethered by GRP75GRP75A chaperone (mortalin) that physically tethers the IP₃ receptor on the ER to VDAC1 on the mitochondrion, aligning the calcium hand-off. to VDAC1VDAC1Voltage-dependent anion channel 1 - the main pore in the outer mitochondrial membrane through which calcium (and metabolites) pass. in the outer mitochondrial membrane, which lines up with the MCUMCUMitochondrial calcium uniporter - the inner-membrane channel that imports calcium into the matrix. in the inner membrane. This is the calcium conduit between the two organelles.

How calcium actually moves
Calcium is not carried “across the ER.” It is released from the ER lumen through the IP₃ receptor into a tightly controlled microdomain in the gap, then imported into the matrix via VDAC1 and the MCU. The route is: ER lumen → IP₃R → MAM microdomain → VDAC1 → intermembrane space → MCU → matrix.
This tether and route are
The contact site

Sigma-1, the stress-sensitive chaperone

ER lumen(calcium store)ER membraneCytosolic gap · MAMmembranes approach - they do not fuseOuter membraneMatrix(TCA cycle)GRP75IP₃RVDAC1MCUSigma-1BiP

The sigma-1 receptorsigma-1 receptorAn ER-resident chaperone protein (not a classical surface receptor) that senses cellular stress and regulates calcium signalling and ion channels. is not a conventional surface receptor. It is an ER-resident chaperone that sits at the MAM and senses the cell's state. In the resting condition it is held in a complex with another chaperone, BiP/GRP78, and ER calcium is relatively stable.

When the cell is stressed - or when a sigma-1 ligand binds - the receptor changes conformation and dissociates from BiP. Freed, it helps stabilise IP₃-receptor signalling at the contact site, supporting a controlled pulse of calcium into the mitochondrion rather than a disorganised flood.

Toggle the state on the diagram: watch BiP release and a measured calcium pulse begin. This regulation of calcium and cell survival is the receptor's established job - the part of the story that does not depend on DMT at all.

Established broader mechanism
The sigma-1 receptor regulates proteins and calcium signalling at ER-mitochondrial contact sites. This is well-supported chaperone biology.
The sigma-1 chaperone mechanism is
The ligand

DMT enters the system

ER lumen(calcium store)ER membraneCytosolic gap · MAMmembranes approach - they do not fusehigh-Ca²⁺ microdomainOuter membraneMatrix(TCA cycle)GRP75IP₃RVDAC1MCUSigma-1BiP
Ca²⁺Route: ER lumen → IP₃R → MAM microdomain → VDAC1 → intermembrane space → MCU → matrix
N,N-dimethyltryptamine

DMT is a small indole molecule - structurally a cousin of serotonin - and it is endogenous: mammalian tissue can make it. Among its targets is the sigma-1 receptor, where it acts as a ligand, engaging the very chaperone we have just met at the MAM.

When DMT binds, it can drive the same conformational shift that stress does: BiP releases, and sigma-1 is positioned to influence IP₃-receptor calcium signalling. That gives DMT a route into cellular stress biology, even though that route is only one part of the cluster headache question.

Experimental
DMT binds the sigma-1 receptor. It was identified as an endogenous sigma-1 ligand in direct binding and functional experiments.
Two things this does not mean
  • The sigma-1 receptor is not “the DMT receptor.” It binds many synthetic and endogenous ligands; DMT is one of them.
  • We deliberately assign no precise affinity, occupancy or activation threshold here, because those numbers only mean something tied to a specific experiment and concentration.
That DMT binds sigma-1 is
Hypoxia

Oxygen begins to fall

Oxygen availabilityNormoxia
100%

Slide from oxygen-replete to near-anoxic and watch the cascade.

O₂ reaching Complex IV100%
Electron-transport flux87%
NADH reduction state38%

rises as the chain backs up

Membrane potential ΔΨm85%
Mitochondrial ATP output74%
Glycolytic reliance0%
Lactate accumulation9%
AMPK activation0%
HIF-1α stabilisation0%
Reactive oxygen species9%

Illustrative model - relative values showing direction and shape, not measured quantities.

Now turn the oxygen down. Because oxygen is the final electron acceptor at Complex IV, its scarcity is felt right along the chain. Electrons cannot be offloaded, so the carriers stay reduced - NADH accumulates relative to NAD⁺. Proton pumping weakens, the membrane potential sags, ATP synthase slows, and mitochondrial ATP output falls.

The cell responds. It leans harder on glycolysis, converts pyruvate to lactate to regenerate NAD⁺, and as ATP drops relative to AMP and ADP, AMPK switches on. Under low oxygen HIF-1α is stabilised, driving a glycolytic adaptation programme. During impaired electron flow - and especially on reoxygenation - reactive oxygen species can rise.

The hard limit
Calcium cannot overcome the absence of oxygen. Oxygen is required at Complex IV for sustained oxidative phosphorylation. No amount of calcium signalling substitutes for the final electron acceptor - a point to hold onto when the proposed rescue mechanism arrives.
A clinical foreshadow
Oxygen's grip on this system is not just theoretical. In cluster headache, the reverse intervention - breathing high-flow oxygen - reliably aborts attacks, even though its mechanism is still unknown. We return to that clinical thread, and to DMT's place in it, in Chapter 13.
Hypoxia

Glycolysis takes emergency priority

NormoxiaHigh ATP
  1. 1Glucose
  2. 2Glycolysis
  3. 3Pyruvate
  4. 4Acetyl-CoA
  5. 5TCA cycle
  6. 6NADH / FADH₂
  7. 7Electron transport chain
  8. 8Oxygen reduced to water
  9. 9Proton gradient → ATP synthase
  10. 10High ATP yield
Hypoxia~2 ATP / glucose
  1. 1Glucose
  2. 2Increased glycolytic reliance
  3. 3Pyruvate
  4. 4Lactate
  5. 5NAD⁺ regenerated
  6. 6~2 ATP per glucose (glycolysis)
Overlays - tap to reveal the adaptation

Select overlays to see how the cell reprogrammes its metabolism.

Under hypoxia the cell reorganises around its fastest oxygen-free option. Pyruvate is diverted to lactate - and this is not simply waste. Reducing pyruvate to lactate regenerates NAD⁺, which glycolysis needs in order to keep producing its small, oxygen-independent trickle of ATP.

At the same time, HIF-1α ramps up glycolytic machinery and induces PDK, which inhibits pyruvate dehydrogenase to keep pyruvate out of an oxygen-starved TCA cycle. The cell is actively conserving oxygen.

A genuine mechanistic tension
The proposed rescue relies on calcium activating pyruvate dehydrogenase and the TCA cycle. But the hypoxic HIF-1α/PDK programme is simultaneously working to inhibit pyruvate dehydrogenase. Any calcium-driven benefit must be reconciled with a cell that is deliberately throttling the same pathway - one reason the full calcium-rescue mechanism remains unproven.
Calcium's activation of these enzymes is
Candidate pathway

A calcium rescue candidate

Proposed pathway - dashed = proposed, not proven
  1. DMT
    Experimental trigger
    The ligand - experimentally a sigma-1 binder.
  2. Sigma-1 receptor engagement
    Experimental trigger
    Experimental: DMT binds sigma-1.
  3. Altered chaperone activity at the MAM
    Established (outside DMT-hypoxia)
    Established sigma-1 biology (outside the DMT-hypoxia experiment).
  4. Stabilised / better-regulated IP₃-receptor signalling
    Established (outside DMT-hypoxia)
    Established sigma-1 chaperone function at the MAM.
  5. Controlled ER-to-mitochondrial Ca²⁺ transfer
    Established (outside DMT-hypoxia)
    Established IP₃R-GRP75-VDAC1-MCU route.
  6. Activation of calcium-sensitive metabolic enzymes
    Established (outside DMT-hypoxia)
    Established: Ca²⁺ activates PDH, IDH, OGDH.
  7. Improved delivery of NADH to the respiratory chain
    Mechanistically inferred
    Mechanistically inferred from the enzyme activation above.
  8. Possible optimisation of residual oxidative phosphorylation (where O₂ remains)
    Mechanistically inferred
    Inferred, and strictly bounded by oxygen availability.
  9. Improved maintenance of ion gradients, membrane integrity and survival
    Mechanistically inferred
    Inferred link to the measured survival outcome.

One candidate pathway sits at the ER-mitochondrial contact site. If DMT engages sigma-1 at the MAM, it might steady the calcium hand-off to the mitochondrion, enough of a controlled pulse to nudge the calcium-sensitive dehydrogenases, improve NADH delivery and make the most of whatever oxygen remains.

Notice what each link is made of. The first two are experimental. The middle links are established biology borrowed from outside the DMT-hypoxia experiment. The last three are inferences - reasonable, but not directly shown in this setting.

The warning that anchors this whole piece
No study has yet demonstrated this complete causal sequence from DMT binding through calcium transfer to increased ATP production during hypoxia.
The complete DMT → calcium → ATP chain is

Two outcomes under the same severe hypoxia

Without protective regulation
  • Disorganised calcium release
  • Mitochondrial calcium overload
  • Excess reactive oxygen species
  • Loss of mitochondrial membrane potential
  • Reduced ATP
  • Failure of Na⁺/K⁺-ATPase and Ca²⁺ pumps
  • Ionic imbalance and membrane depolarisation
  • Swelling; opening of permeability-transition pathways
  • Cytochrome c release
  • Cell injury or death
With proposed sigma-1-mediated regulation
  • More controlled calcium pulses
  • Preserved ER-mitochondrial communication
  • Moderate stimulation of metabolic enzymes
  • Better maintenance of mitochondrial function
  • Less ER stress
  • More stable membrane potential
  • Delayed failure of ATP-dependent ion pumps
  • Improved probability of cell survival

Note the right-hand column is relative improvement: even with perfect regulation, severe hypoxia does not permit normal ATP production. Oxygen is still the limit.

Candidate pathway

Why calcium can protect or destroy

mitochondrial calcium →metabolic drivedamage
50%
Moderate pulse

Pyruvate oxidation and dehydrogenase activity rise; NADH generation increases and output better matches demand.

Dehydrogenase drive100%
ATP output42%
Reactive oxygen species35%
Permeability-transition risk18%

It is tempting to read the calcium pathway as “calcium boosts energy, so more calcium is better.” The biology says otherwise. Calcium's effect is biphasic.

Drag the calcium control across its range. Too little, and the dehydrogenases are under-driven. A moderate pulse sits at the peak of the green curve - metabolism is optimised. Push further and the green curve falls while the red damage curve climbs: ROS, permeability transition, collapsing membrane potential.

This is precisely why regulation, not just calcium, is the point of interest. A controlled pulse lands near the peak; a disorganised flood overshoots into damage.

The point to discover for yourself
“More calcium” is not automatically beneficial. Energy is not created by calcium - calcium regulates throughput. Energy is captured from nutrient oxidation, and oxygen is still required to sustain it.
Evidence

What DMT experiments have actually shown

Step into the lab. Three lines of direct evidence support the DMT-sigma-1 story - and it matters exactly what each one measured, and what it did not. According to the primary literature (verified via PubMed):

Experimental

DMT is a sigma-1 receptor ligand

DMT was identified as an endogenous ligand of the sigma-1 receptor in direct binding and functional assays, including loss of a DMT-induced behaviour in sigma-1 knockout mice.

Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. Science 2009; 323(5916):934-937. doi:10.1126/science.1166127
Experimental · in vitro

Cultured human cells under severe hypoxia

Human cortical neurons derived from induced pluripotent stem cells, together with human macrophages and dendritic cells, were exposed to severe hypoxia at approximately 0.5% oxygen. DMT improved cellular survival, and interference with sigma-1 receptor function reduced or abolished the protective effect.

The experiment demonstrated sigma-1-dependent protection. It did not directly establish increased ATP production as the mechanism.

Szabo A, Kovacs A, Riba J, Djurovic S, Rajnavolgyi E, Frecska E. Frontiers in Neuroscience 2016; 10:423. doi:10.3389/fnins.2016.00423
Preclinical · animal

Experimental cerebral ischaemia

In a rat model, DMT (and the selective sigma-1 agonist PRE-084) showed neuroprotective effects, attenuating spreading depolarisation and reducing cell death; the sigma-1 antagonist NE-100 blocked the effect.

Animal ischaemia findings cannot be assumed to demonstrate the same mechanism, dose response or clinical benefit in humans.

Szabó Í, Varga VÉ, Dvorácskó S, Farkas AE, Körmöczi T, Berkecz R, et al. Neuropharmacology 2021; 192:108612. doi:10.1016/j.neuropharm.2021.108612

Read together, these are genuinely encouraging results for a sigma-1-dependent protective effect. What none of them did was measure ATP or calcium flux as the causal mechanism under hypoxia. That is why the calcium→ATP story remains an unresolved candidate mechanism, not a demonstrated fact.

Clinical signal

The clinical thread: cluster headache

Cluster headache gives this biology its urgency. It is among the most severe pain conditions in medicine, often strictly circadian, and shaped by the hypothalamus, the trigeminovascular system and the trigeminal-autonomic reflextrigeminal-autonomic reflexA brainstem reflex linking trigeminal pain pathways to cranial parasympathetic output - responsible for the tearing, congestion and eye changes of a cluster attack.. In patient communities, inhaled or vaped DMT is described as a rapid abortive for some attacks, and an interim international survey has now reported that signal in the clinical literature.

The question is not whether one receptor explains everything. The better question is what layers of biology could plausibly be involved: acute serotonin-linked neural signalling, trigeminal and autonomic circuitry, known abortives such as oxygen and triptans, and slower stress systems that may influence vulnerability between attacks.

Two biological timescales
ACUTE ABORTIVE PATHWAYDMTinhaled signalserotonin gate5-HT2A signalling5-HT1B/1D familyattackloophypothalamustrigeminalCGRPautonomicsigma-1 / MAMcalcium stress handlingredox energyminutes to hours1 s10 s1 min10 min1 h→ days-weeksFast lane: serotonergic neural gatingreceptor signalling · reflex reset · ion-channel modulationSlow terrain: MAM calcium · bioenergetics · survival signallingDMT: secondsoxygen: minutesprevention

Acute abortive effects belong to fast neural signalling. Slower mitochondrial, redox and methylation biology may still shape the terrain that makes an attack easier or harder to ignite.

A cluster abortive has to influence the attack network quickly. That points first toward fast receptor and circuit biology: serotonergic signalling, trigeminovascular gating, brainstem/autonomic output and ion-channel modulation.

DMT sits in that space because it is a serotonergic tryptamine. Its actions at 5-HT2A and other serotonin-linked systems are therefore central to the acute question. Sigma-1 remains relevant too, especially because it can modulate ion channels quickly and shape cellular stress responses more slowly.

The most honest anchor of all
Even oxygen, the established first-line abortive, still has an incompletely explained mechanism. A double-blind trial found it does not act through the parasympathetic reflex arc, and it has no effect on ordinary pain. That is the right level of humility for DMT too: clinically interesting, biologically plausible, but not yet mechanistically settled.

What the clinical record actually shows

Oxygen - fast, proven, unexplained

High-flow oxygen reliably aborts attacks and is first-line therapy - but its mechanism remains unknown, and it does not act via the parasympathetic reflex arc tested.

Schröder CF et al. Cephalalgia 2023. doi:10.1177/03331024231161269

Psilocybin / LSD - a preventive signal

Survey and a small RCT suggest classic tryptamines can suppress cluster periods over days-weeks. Tellingly, benefit was uncorrelated with the intensity of the psychedelic experience - hinting the therapeutic action is separable from the “trip.”

Sewell RA et al. Neurology 2006. doi:10.1212/01.wnl.0000219761.05466.43

Schindler EAD et al. Headache 2022. doi:10.1111/head.14420

DMT - the rapid-abort signal

Patient reports, now supported by an interim international survey, describe rapid attack relief with DMT, commonly by inhaled/vaped use. Compelling as a signal; still not controlled evidence and not a mechanism study.

Schindler E et al. Neurology 2026. doi:10.1212/WNL.0000000000215894

Two speeds, different jobs
The fast layer includes serotonergic receptor signalling, trigeminovascular gating, brainstem/autonomic output and possibly sigma-1 ion-channel modulation. The slower layer includes MAM calcium, redox handling, serotonin-driven mitochondrial adaptation and methylation-linked melatonin/DMT chemistry. Both can matter without either being the whole story.
Not medical advice
This section explains cell biology and clinical observations. It is not medical advice and not a recommendation to use DMT, which is a controlled substance in most jurisdictions. Cluster headache is serious; effective, legal treatments exist (including high-flow oxygen and triptans) and belong in the hands of a clinician.
The bridge

The serotonin-melatonin energy axis

Two faces of serotonin
Extracellular serotonin: signal and adaptationIntracellular serotonin: mitochondrial stress biologySerotonin5-HT2ASIRT1 / PGC-1alphamorecapacityHours to days: biogenesis, ATP capacity, antioxidant enzymesSerotoninMelatoninMitochondrial resiliencestressbufferHypothesis lane: useful for questions, not established as a DMT cluster-abort mechanism

The fast cluster-abort question and the slower mitochondrial-stress question should not be collapsed into one pathway.

Masterjohn's useful contribution is not a new proof of the DMT mechanism. It is a map: serotonin can be read as both a surface signal and a mitochondrial stress signal. That matters because DMT, psilocin, serotonin and melatonin all sit close to the same biochemical neighbourhood.

The most solid piece for this documentary is the 5-HT2A-to-mitochondria lane. In rodent cortical neurons, serotonin and 5-HT2A stimulation regulated mitochondrial biogenesis, ATP-related measures and oxidative stress resilience through the SIRT1/PGC-1alpha axis. That is real biology, but it is slower adaptation rather than a seconds-fast abort.

How this relates to cluster headache
Cluster headache is strongly circadian, oxygen-responsive and hypothalamic. A serotonin-melatonin energy axis gives the documentary a credible bridge between 5-HT2A pharmacology, melatonin/circadian biology and mitochondrial vulnerability without pretending that one receptor explains the whole disease.
The 5-HT2A mitochondrial-biogenesis finding is
Interpretations and hypotheses

Popular science discussions (for example, commentary by Chris Masterjohn and others) have proposed broader serotonin-melatonin, hypoxia and mitochondrial interpretations. Those syntheses are useful for forming questions, but they are presented here as interpretations to be tested against primary literature, not as sources establishing the mechanism.

Masterjohn commentary

Fanibunda SE et al. Proceedings of the National Academy of Sciences 2019. doi:10.1073/pnas.1821332116

Cluster terrain

The metabolic terrain underneath the attack

A 2026 study of cerebrospinal-fluid metabolites adds a wider layer to the cluster-headache story. Instead of looking at one drug or one receptor, it used genetic evidence to ask which central metabolic signals may be associated with cluster-headache risk.

That matters for this documentary because DMT's reported abortive effect sits inside a nervous system that is already oxygen-sensitive, circadian, pain-amplifying and metabolically demanding. The study's signals point toward redox pressure, mitochondrial energy metabolism, methylation, lipid signalling and the tryptophan/kynurenine pathway. These are not a replacement for serotonin or sigma-1 biology. They are the terrain those mechanisms operate within.

The redox signal
CSF METABOLITE TERRAINRedox5-oxoprolineEnergyOrotate+ 3-HMGMethylationBetaineLipid signalling1-oleoyl-GPC+ arachidonateTryptophan pathKynurenineAmino acidsGlu + Cys + GlyGSHreduced glutathioneROS bufferedoxidative pressureGSSGoxidised glutathioneNADPHrecycling power5-oxoprolineMR redox signalTerrain, not a diagnostic test: a map of plausible vulnerability biology.
Why show glutathione?
The MR paper's strongest readable redox clue is 5-oxoproline, a molecule in the gamma-glutamyl cycle around glutathione turnover. It does not prove oxidative stress causes cluster attacks. It says glutathione/redox biology belongs on the map.
Redox
5-oxoproline

Glutathione turnover and oxidative-stress pressure

Energy
Orotate / 3-HMG

Mitochondrial and intermediary metabolism

Methylation
Betaine

Methyl-donor chemistry relevant to melatonin and DMT synthesis

Lipid signalling
1-oleoyl-GPC / arachidonate

Membrane signalling and inflammatory tone

Tryptophan path
Kynurenine

Neuroimmune diversion from serotonin/melatonin chemistry

The MR terrain finding is

Yu D et al. Journal of Pain Research 2026. doi:10.2147/JPR.S550160

How it fits the DMT question
The DMT question is acute: what could change the attack circuit quickly enough to abort pain? The metabolite study asks a background question: what biochemical environment may make that circuit vulnerable in the first place? Together they point to a fuller model, fast neural signalling on top of slower redox, mitochondrial and methylation biology.
What this study cannot say
The study is preliminary genetic epidemiology. It did not measure CSF during attacks, did not test DMT, did not measure ATP or glutathione flux directly, and cannot tell an individual patient what will work.
Related field

The Alzheimer's connection

Disturbances studied at the ER-mitochondrial interface in Alzheimer's
Altered MAM organisation
Abnormal calcium transfer
Amyloid-associated stress
Tau-related mitochondrial dysfunction
Reduced glucose utilisation
Mitochondrial respiratory dysfunction
Oxidative stress
Synaptic energy failure
These are associated disturbances across a multifactorial disease - not a single causal chain, and not evidence about DMT.
Area-Gomez E, Schon EA. Current Opinion in Genetics & Development 2016; 38:90-96. doi:10.1016/j.gde.2016.04.006

Why does a story about cluster headache, DMT and hypoxia touch Alzheimer's disease at all? Because Alzheimer's research is a mature field for the same cell-stress machinery now appearing in the cluster-headache metabolic terrain: mitochondrial metabolism, calcium homeostasis, oxidative stress and ER-mitochondrial contact sites - the MAM we have been standing inside.

Sigma-1 receptor agonism is being investigated as a possible way to influence these systems. That is a reason for scientific interest in sigma-1 biology broadly. It is not evidence that DMT treats, prevents or reverses Alzheimer's disease, and it is not a claim that cluster headache is an Alzheimer's-like disease.

Related field - not direct DMT proof
Alzheimer's disease research increasingly examines disrupted mitochondrial metabolism, calcium homeostasis and ER-mitochondrial contact sites, and sigma-1 agonism is being explored as a potential modulator. This does not establish DMT as an Alzheimer's treatment, does not explain cluster headache by analogy, and does not reduce either disease to one pathway.
The MAM-Alzheimer's link is
Evidence

What remains unresolved

Let us be exact about the edge of what is known. It is established that sigma-1 regulates MAM calcium signalling and survival, and that calcium activates the matrix dehydrogenases. It is experimental that DMT binds sigma-1 and improves survival of hypoxic human cells in a sigma-1-dependent way, that serotonin can affect neuronal mitochondria through 5-HT2A in rodents, and that cluster headache now has preliminary CSF-metabolite genetic signals. Everything that stitches these into a single “DMT aborts cluster headache by this exact pathway” mechanism is still inference or unresolved mechanism.

Open questions a decisive experiment would answer
  • Does DMT measurably increase controlled ER→mitochondrial calcium transfer in hypoxic human neurons?
  • Is ATP actually higher with DMT under hypoxia - measured directly, not inferred?
  • Is any benefit dependent on calcium-driven dehydrogenase activation, or on other sigma-1 actions (antioxidant, anti-ER-stress, HIF-related)?
  • Does the rapid cluster abort track 5-HT2A, 5-HT1B/1D, sigma-1 ion-channel modulation, or a convergent network reset?
  • Do CSF or plasma redox and methylation markers shift before, during or after cluster attacks?
  • Do endogenous DMT concentrations ever reach levels that engage sigma-1 in the living human brain?
  • How is a calcium-driven push on pyruvate dehydrogenase reconciled with the hypoxic PDK programme that inhibits it?
The calcium→ATP mechanism is· endogenous-DMT rise is
What this piece will not claim
We do not state that the pineal gland releases a large amount of DMT during hypoxia, near-death experiences, dreaming or death. Those claims are not established.
Interpretations and hypotheses

Popular science discussions (for example, commentary by Chris Masterjohn and others) have proposed broader serotonin-melatonin, hypoxia and mitochondrial interpretations. Those syntheses are useful for forming questions, but they are presented here as interpretations to be tested against primary literature, not as sources establishing the mechanism.

Falsifiable predictions

An unresolved mechanism becomes useful when it can be tested clearly. Each prediction below is designed so that a single experiment could push the idea toward, or off, the table.

Fast vs slow: a selective sigma-1 agonist (e.g. PRE-084) should abort attacks as fast as DMT.
Supports:If a seconds-fast abort is truly sigma-1-mediated, a clean sigma-1 agonist reproduces it.
Refutes:If only DMT (with its serotonergic and Na⁺-channel actions) aborts in seconds, the abort is not principally the sigma-1/calcium mechanism.
Calcium dependence: blocking the MCU should blunt any DMT benefit that runs through matrix calcium.
Supports:If DMT's protection needs mitochondrial calcium uptake, MCU inhibition weakens it.
Refutes:If DMT still protects with the MCU blocked, the benefit is not calcium-into-matrix driven.
Direct measurement: hypoxic human neurons given DMT should show a measurable, sigma-1-dependent rise in ATP.
Supports:Direct ATP/Ca²⁺ imaging showing the predicted pulse and ATP change would elevate the mechanism from inferred to demonstrated.
Refutes:No ATP change (despite survival benefit) would show protection works by another route entirely.
Endogenous rise: sensitive LC-MS/MS should detect a hypoxia-driven increase in brain DMT to sigma-1-relevant levels.
Supports:A reproducible rise into the effective range would make the endogenous story physiologically real.
Refutes:No meaningful rise would confine endogenous DMT to a bystander, not a hypoxia signal.
Shared node: if oxygen and DMT abort attacks through the same pathway, their effects should be non-additive or cross-tolerant.
Supports:Non-additivity would suggest a converging mechanism.
Refutes:Clean additivity would suggest independent routes to the same relief.
Separable from the trip: therapeutic effect should not track the intensity of the psychedelic experience.
Supports:Already hinted in the psilocybin trial - sub-threshold dosing working would strengthen this.
Refutes:If benefit scales tightly with subjective intensity, a central 'experience' mechanism dominates.
Interactive

Explore the cell yourself

Drive the whole system. Change oxygen, add DMT, block sigma-1, the IP₃ receptor or the MCU, and watch the contact site and the cell's state respond. This is a teaching model - the numbers show direction and shape, not measured quantities.

Oxygen-replete neuron meeting its energy budget by oxidative phosphorylation.

100%
0%
70%
50%
50%
ER lumen(calcium store)ER membraneCytosolic gap · MAMmembranes approach - they do not fusehigh-Ca²⁺ microdomainOuter membraneMatrix(TCA cycle)GRP75IP₃RVDAC1MCUSigma-1BiPCa²⁺Route: ER lumen → IP₃R → MAM microdomain → VDAC1 → intermembrane space → MCU → matrix
Illustrative cell state - Normoxia
Probability the cell holds its gradients92%
Total ATP supply61%
Oxidative ATP64%
Glycolytic ATP32%

oxygen-independent

Membrane potential80%
Matrix calcium55%
Regulation quality72%
Reactive oxygen species9%
Permeability-transition risk1%

Values are illustrative outputs of a teaching model, not a validated physiological simulation.

Sources

Evidence map & references

Evidence map

Every major claim in this documentary, sorted by how strongly it is supported. Click any badge to see what was measured, in what model, and whether DMT, ATP or calcium flux were directly tested.

Established cell biology
  • The sigma-1 receptor is a Ca²⁺-sensitive chaperone at the MAM that regulates ER→mitochondrial Ca²⁺ signalling via IP₃ receptors.

  • Matrix Ca²⁺ activates pyruvate, isocitrate and α-ketoglutarate dehydrogenases, increasing TCA-cycle throughput.

  • ER Ca²⁺ is released through IP₃ receptors into a MAM microdomain and taken up via VDAC1 and the mitochondrial calcium uniporter (MCU).

  • The sigma-1 receptor rapidly modulates voltage- and ligand-gated ion channels to tune neuronal excitability.

Direct experimental finding
  • DMT binds and acts at the sigma-1 receptor.

  • DMT improved survival of human cells under severe hypoxia through a sigma-1-dependent mechanism.

  • DMT attenuated spreading depolarization and reduced cell death in a rat model of cerebral ischaemia, via sigma-1 receptors.

  • High-flow oxygen aborts cluster-headache attacks - yet its mechanism of action is still unknown.

  • Classic tryptamine psychedelics (psilocybin, LSD) show a signal for suppressing cluster-headache periods.

  • Serotonin and 5-HT2A receptor stimulation can regulate mitochondrial biogenesis and function in rodent cortical neurons.

  • A 2026 CSF metabolite Mendelian-randomization study linked redox, energy, methylation and lipid-signalling metabolites with cluster-headache risk.

Mechanistic inference
  • Disrupted MAM function, calcium handling and mitochondrial metabolism are implicated in Alzheimer's disease; sigma-1 agonism is being investigated.

Unresolved mechanism
  • DMT protects hypoxic cells specifically by increasing calcium-driven ATP production through TCA-cycle stimulation.

  • Patients report that inhaled DMT can abort cluster attacks rapidly, sometimes at sub-psychedelic doses.

  • How a substance could abort a cluster attack within seconds is not established for DMT - or, mechanistically, even for oxygen.

  • Hypoxia might raise endogenous brain DMT by slowing its oxygen-dependent clearance.

The neuron, still alive under constrained oxygen

Three pathways run at once in the surviving cell.

Glycolysis
  1. 1Glucose
  2. 2Pyruvate ↔ Lactate
  3. 3~2 ATP

Small but oxygen-independent ATP supply.

Residual oxidative phosphorylation
  1. 1NADH / FADH₂
  2. 2Electron transport
  3. 3ATP (O₂-limited)

Higher ATP efficiency, but limited by available oxygen.

Stress response & metabolic terrain
  1. 1Sigma-1 / 5-HT signalling
  2. 2Redox and methylation state
  3. 3Preserved function?

Possible terrain for vulnerability and resilience.

In closing

DMT has demonstrated sigma-1-receptor-dependent protection in experimental hypoxia and now has a formal patient-reported cluster headache signal. The fast abort is better treated as a serotonergic and neural-gating question, while sigma-1, MAM calcium, serotonin, melatonin, redox balance and methylation define the slower metabolic terrain that may make the attack circuit vulnerable.

References

Citations were checked against source-of-record metadata. DOIs link to the source of record; PubMed links are included where available.

  1. [1]

    The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator.

    Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. Science 2009; 323(5916):934-937.

    Primary evidence that DMT binds and acts at the sigma-1 receptor.

  2. [2]

    Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca²⁺ signaling and cell survival.

    Hayashi T, Su TP. Cell 2007; 131(3):596-610.

    Establishes the sigma-1 receptor as a Ca²⁺-sensitive, ligand-operated chaperone at the MAM that regulates IP₃R-mediated ER→mitochondrial Ca²⁺ signalling and cell survival.

  3. [3]

    The endogenous hallucinogen and trace amine N,N-dimethyltryptamine (DMT) displays potent protective effects against hypoxia via sigma-1 receptor activation in human primary iPSC-derived cortical neurons and microglia-like immune cells.

    Szabo A, Kovacs A, Riba J, Djurovic S, Rajnavolgyi E, Frecska E. Frontiers in Neuroscience 2016; 10:423.

    In vitro: DMT increased survival of human iPSC-derived cortical neurons, macrophages and dendritic cells under severe hypoxia (0.5% O₂); the effect was sigma-1-dependent and associated with reduced HIF-1α (HIF-1-independent protection). ATP was not the measured endpoint.

  4. [4]

    N,N-dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain.

    Szabó Í, Varga VÉ, Dvorácskó S, Farkas AE, Körmöczi T, Berkecz R, et al. Neuropharmacology 2021; 192:108612.

    Preclinical (rat): DMT and the selective sigma-1 agonist PRE-084 attenuated spreading depolarization and reduced apoptotic/ferroptotic cell death after global forebrain ischaemia; effects blocked by the sigma-1 antagonist NE-100.

  5. [5]

    Regulation of mitochondrial dehydrogenases by calcium ions.

    Denton RM. Biochimica et Biophysica Acta (Bioenergetics) 2009; 1787(11):1309-1316.

    Review of Ca²⁺ activation of the three matrix dehydrogenases - pyruvate dehydrogenase (via pyruvate dehydrogenase phosphatase), NAD-isocitrate dehydrogenase and α-ketoglutarate dehydrogenase.

  6. [6]

    Mitochondria as sensors and regulators of calcium signalling.

    Rizzuto R, De Stefani D, Raffaello A, Mammucari C. Nature Reviews Molecular Cell Biology 2012; 13(9):566-578.

    Review of the IP₃R-GRP75-VDAC1 tether, MAM Ca²⁺ microdomains, MCU-mediated matrix uptake, and the double-edged role of mitochondrial Ca²⁺ in metabolism versus permeability transition.

  7. [7]

    Mitochondria-associated ER membranes and Alzheimer disease.

    Area-Gomez E, Schon EA. Current Opinion in Genetics & Development 2016; 38:90-96.

    Review linking altered MAM function, calcium handling and lipid/energy metabolism to Alzheimer's disease pathophysiology. Does not concern DMT.

  8. [8]

    Response of cluster headache to psilocybin and LSD.

    Sewell RA, Halpern JH, Pope HG Jr. Neurology 2006; 66(12):1920-1922.

    Interview series of 53 cluster-headache patients: most psilocybin users reported attack abortion, cluster-period termination and remission extension. Retrospective, self-reported and signal-generating, not a controlled trial.

  9. [9]

    Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial.

    Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Zhu Y, et al. Headache 2022; 62(10):1383-1394.

    Small RCT of a psilocybin pulse for cluster-headache suppression. Primary efficacy outcome negative (n small); moderate effect size, larger in chronic patients. Crucially, benefit was NOT correlated with the intensity of acute psychedelic effects - separating therapeutic action from the 'trip'.

  10. [10]

    Oxygen inhalation has no effect on provoked cranial autonomic symptoms using kinetic oscillation stimulation in healthy volunteers.

    Schröder CF, Basedau H, Moeller M, May A. Cephalalgia 2023; 43(4):3331024231161269.

    Double-blind RCT: 100% oxygen - the first-line cluster abortive - did NOT modify the trigeminal-autonomic parasympathetic reflex arc. The authors note oxygen has no effect on nociceptive pain and that its mechanism of action in cluster headache is still unknown.

  11. [11]

    Sigma-1 receptor and neuronal excitability.

    Kourrich S. Handbook of Experimental Pharmacology 2017; 244:109-130.

    Review of how sigma-1 rapidly modulates voltage-gated and ligand-gated ion channels (Na⁺, K⁺, Ca²⁺, NMDA, AMPA) to fine-tune neuronal excitability - a fast signalling mode distinct from the slower MAM chaperone/metabolic actions.

  12. [12]

    Migraine and cluster headache - the common link.

    Vollesen AL, Benemei S, Cortese F, Labastida-Ramírez A, Marchese F, Pellesi L, et al. The Journal of Headache and Pain 2018; 19(1):89.

    Review of cluster/migraine pathophysiology: the trigeminovascular system, CGRP, hypothalamic involvement, triptan and neuromodulation response, and the cranial-autonomic (trigeminal-autonomic) reflex.

  13. [13]

    Bidirectional Mendelian Randomization Analysis of 338 Cerebrospinal-Fluid Metabolites and Cluster-Headache Risk.

    Yu D, Yang X, Zhou J, Chen W, Song J, Yu W, Huang S. Journal of Pain Research 2026; 19:550160.

    Two-sample bidirectional Mendelian-randomization study linking genetically predicted CSF metabolites involved in redox stress, mitochondrial/energy metabolism, methylation and lipid signalling with cluster-headache risk. Preliminary and population-level, not a DMT study.

  14. [14]

    DMT use in Cluster Headache: Interim Analysis of an International Survey (S23.003).

    Schindler E, Lenaburg K, Wold R. Neurology 2026; 106(11 Suppl 1):2531.

    Interim international survey on DMT use in adults with cluster headache. It supports the patient-reported rapid-abort signal, but remains self-reported survey evidence rather than a controlled clinical trial or mechanism study.

  15. [15]

    Serotonin regulates mitochondrial biogenesis and function in rodent cortical neurons via the 5-HT2A receptor and SIRT1-PGC-1alpha axis.

    Fanibunda SE, Deb S, Maniyadath B, Tiwari P, Ghai U, Gupta S, et al. Proceedings of the National Academy of Sciences 2019; 116(22):11028-11037.

    Rodent-neuron evidence that serotonin and 5-HT2A receptor stimulation can regulate mitochondrial biogenesis, ATP levels, respiration and oxidative-stress resilience through SIRT1/PGC-1alpha. This is slower adaptive biology, not proof of a seconds-fast cluster abort.